GSK-Backed Sitryx Launches With Six Immunometabolism Eggs In Its Basket
GlaxoSmithKline, SV Health Investors and Sofinnova are among the backers of a new Oxford-based biotech which has raised $30m in series A financing and boasts a strong line-up of academic founders. CEO Neil Weir outlines Sitryx's raison d'etre.
You may also be interested in...
Lilly is prepared to splash over $600m on an early development deal with ImmuNext on an immunometabolism target which ties the companies together for three years while an antibody is being developed.
Paul Peter Tak recently defected from big pharma to East Coast venture firm Flagship Pioneering. He described the appeal of entrepreneurship in the biotech world and the value of taking the road less traveled when it comes to biomedical R&D.
With $46m funding fresh in its pocket, Dublin biotech Inflazome tells Scrip how it will advance its clinical candidates in multiple indications.